Scpharmaceuticals Inc (SCPH)

NASDAQ
Currency in USD
4.380
-0.090(-2.01%)
Closed·
After Hours
4.3800.000(0.00%)
·
SCPH Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
SCPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.3804.570
52 wk Range
1.9405.650
Key Statistics
Edit
Prev. Close
4.47
Open
4.48
Day's Range
4.38-4.57
52 wk Range
1.94-5.65
Volume
336.25K
Average Volume (3m)
328.27K
1-Year Change
-4.78%
Book Value / Share
-0.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SCPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.600
Upside
+256.16%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Scpharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Scpharmaceuticals Company Profile

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Employees
163

Scpharmaceuticals Inc Earnings Call Summary for Q1/2025

  • SC Pharmaceuticals missed Q1 2025 forecasts with EPS of -$0.36 and revenue of $11.8M, despite 167% YoY growth
  • Furosex product launched in chronic kidney disease market in April 2025, driving revenue growth and sales force expansion
  • Cash and equivalents decreased to $57.5M from $75.7M in December 2024, raising concerns about rapid cash burn
  • Company expects Q2 2025 to outpace Q1, projecting continued revenue growth in nephrology and heart failure markets
  • Prescription fill rates improved from 46% in Q1 to 55% in April, indicating positive momentum in product uptake
Last Updated: 15-05-2025, 02:54 am
Read Full Transcript

Compare SCPH to Peers and Sector

Metrics to compare
SCPH
Peers
Sector
Relationship
P/E Ratio
−2.5x−2.2x−0.5x
PEG Ratio
0.100.000.00
Price/Book
−45.1x2.2x2.6x
Price / LTM Sales
5.5x2.0x3.1x
Upside (Analyst Target)
174.0%128.5%46.1%
Fair Value Upside
Unlock23.9%6.9%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.600
(+256.16% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.36 / -0.32
Revenue / Forecast
11.80M / 12.83M
EPS Revisions
Last 90 days

SCPH Income Statement

FAQ

What Is the Scpharmaceuticals (SCPH) Stock Price Today?

The Scpharmaceuticals stock price today is 4.38.

What Stock Exchange Does Scpharmaceuticals Trade On?

Scpharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Scpharmaceuticals?

The stock symbol for Scpharmaceuticals is "SCPH."

What Is the Scpharmaceuticals Market Cap?

As of today, Scpharmaceuticals market cap is 231.23M.

What Is Scpharmaceuticals's Earnings Per Share (TTM)?

The Scpharmaceuticals EPS (TTM) is -1.88.

When Is the Next Scpharmaceuticals Earnings Date?

Scpharmaceuticals will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is SCPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Scpharmaceuticals Stock Split?

Scpharmaceuticals has split 0 times.

How Many Employees Does Scpharmaceuticals Have?

Scpharmaceuticals has 163 employees.

What is the current trading status of Scpharmaceuticals (SCPH)?

As of 12 Jul 2025, Scpharmaceuticals (SCPH) is trading at a price of 4.38, with a previous close of 4.47. The stock has fluctuated within a day range of 4.38 to 4.57, while its 52-week range spans from 1.94 to 5.65.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.